The Effect Of NS-0200 Versus Placebo On Hepatic Fat Content In Patients With Non Alcoholic Fatty Liver Disease
Status:
Completed
Trial end date:
2017-01-31
Target enrollment:
Participant gender:
Summary
The goal of this study is to determine if NS-0200 can reduce the amount of liver fat in
patients diagnosed with non-alcoholic fatty liver disease (NAFLD). This study will compare
two doses of NS-0200 to placebo in NAFLD patients.